|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Taris_Biomedical
gptkb:Actelion
Tremont Therapeutics
|
|
gptkbp:ceo
|
gptkb:Mathai_Mammen
|
|
gptkbp:clinical_trial
|
gptkb:vaccine
depression treatment
HIV treatment
psoriasis treatment
Alzheimer's disease treatment
schizophrenia treatment
Crohn's disease treatment
multiple myeloma treatment
ulcerative colitis treatment
pulmonary arterial hypertension treatment
|
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:Yale_University
|
|
gptkbp:focus_area
|
oncology
neuroscience
cardiovascular diseases
biopharmaceuticals
infectious diseases
immunology
pulmonary hypertension
metabolic diseases
|
|
gptkbp:founded
|
gptkb:2002
|
|
gptkbp:headquarters
|
gptkb:Beerse,_Belgium
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Janssen Research & Development
|
|
gptkbp:number_of_employees
|
over 10,000
|
|
gptkbp:operating_income
|
$1.5 billion (2020)
|
|
gptkbp:parent_company
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:part_of
|
Johnson & Johnson Pharmaceutical Research & Development
|
|
gptkbp:product
|
gptkb:Xarelto
gptkb:Stelara
gptkb:Remicade
gptkb:Tremfya
gptkb:Invega
Darzalex
Simponi
Janssen COVID-19 vaccine
|
|
gptkbp:research_and_development_budget
|
$2.5 billion (2020)
|
|
gptkbp:revenue
|
$12.5 billion (2020)
|
|
gptkbp:website
|
www.janssen.com
|
|
gptkbp:bfsParent
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:bfsLayer
|
5
|